MAC
XBI icon

Mason & Associates (California)’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Mason & Associates (California)’s Portfolio XBI Stock Details XBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2,585
Closed -$232K – 114
2022
Q1 		$232K Buy
+2,585
New +$239K 0.07% 102

Other funds holding XBI

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Mason & Associates (California)'s XBI Position: Q2 2022 in Review

Mason & Associates (California) sold out of State Street SPDR S&P Biotech ETF (XBI) in Q2 2022, closing a stake of 2,585 shares — an estimated $232K sold.

Mason & Associates (California) first reported a position in XBI in Q1 2022 and held it in 1 quarter. The position peaked at $232K in Q1 2022. 706 funds tracked by Wall St. Rank hold XBI as of Q2 2022.

  • Mason & Associates (California) reported no remaining State Street SPDR S&P Biotech ETF position as of Q2 2022 after selling out during the quarter.
  • Mason & Associates (California) sold 2,585 State Street SPDR S&P Biotech ETF shares in Q2 2022, an estimated $232K.
  • Mason & Associates (California) first reported a position in State Street SPDR S&P Biotech ETF in Q1 2022 and held it in 1 quarter.
  • Mason & Associates (California)'s State Street SPDR S&P Biotech ETF position peaked at $232K in Q1 2022.
  • 706 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2022.

Based on Mason & Associates (California)'s 13F filing for Q2 2022, filed 26 Jul 2022.